For authorized biosimilars to achieve full acceptance in the marketplace, it is crucial that they are considered to be therapeutically equivalent and interchangeable with the brand reference product.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Assessing the Immunogenicity of Biopharmaceuticals
BioDrugs Open Access 20 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
European Commission. Off. J. Eur. Union L136, 34–57 (2004).
Health, I.M.S. Shaping the Biosimilars Opportunity: a Global Perspective on the Evolving Biosimilars Landscape (IMS Health, New York, USA, 2011; accessed 11 April 2012). <http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf>
European Medicines Agency. Volume 9A of The Rules Governing Medicinal Products in the European Union. (EMA, London, 2008; accessed 2 August 2012). <http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf>
European Commission. Off. J. Eur. Union L311, 67–267 (2001).
European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMA, London, 2007; accessed 3 July 2012). <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003947.pdf>
Casadevall, N. et al. N. Engl. J. Med. 346, 469–475 (2002).
Gascon, P. et al. Ann. Oncol. 21, 1419–1429 (2010).
European Medicines Agency. EPARs for Authorised Medicinal Products for Human Use (EMA, London; accessed 9 September 2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
Frau, S., Font Pous, M., Luppino, M.R. & Conforti, A. Eur. J. Clin. Pharmacol. 66, 785–790 (2010).
Haag-Weber, M. et al. Clin. Nephrol. 77, 8–17 (2012).
Seidl, A. et al. Pharm. Res. 29, 1454–1467 (2012).
Jiang, Y. et al. J. Pharm. Sci. 98, 4695–4710 (2009).
Praditpornsilpa, K. et al. Kidney Int. 80, 88–92 (2011).
Peterson, G.M. Br. J. Clin. Pharmacol. 71, 966–967, author reply 968 (2011).
Meredith, P.A. Curr. Med. Res. Opin. 25, 2179–2189 (2009).
Walsh, G. Drug Discov. Today 15, 773–780 (2010).
European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/42832/2005 (EMA, London, 2006; accessed 26 July 2012). <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf>
European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (EMA, London, 2006). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf
Covic, A. et al. Nephrol. Dial. Transplant. 23, 3731–3737 (2008).
Rovira, J., Espin, J., Garcia, L. & Olry de Labry, A. The Impact of Biosimilars' Entry in the EU Market (Andalusian School of Public Health, Spain, 2011).
Niederwieser, D. & Schmitz, S. Eur. J. Haematol. 86, 277–288 (2011).
Minghetti, P., Rocco, P., Del Vecchio, L. & Locatelli, F. Nephron Clin. Pract. 117, c1–c7 (2011).
Brinks, V. et al. Pharm. Res. 28, 386–393 (2011).
Storring, P.L. et al. Br. J. Haematol. 100, 79–89 (1998).
Schiestl, M. et al. Nat. Biotechnol. 29, 310–312 (2011).
Vanrenterghem, Y. et al. Kidney Int. 62, 2167–2175 (2002).
Dellanna, F. et al. Int. J. Clin. Pract. 65, 64–72 (2011).
Ebbers, H.C., Muenzberg, M. & Schellekens, H. Exp. Opin. Biol. Ther. 12, 1473–1485 (2012).
Duerden, M.G. & Hughes, D.A. Br. J. Clin. Pharmacol. 70, 335–341 (2010).
Kresse, G.B. Eur. J. Pharm. Biopharm. 72, 479–486 (2009).
Declerck, P.J. et al. Curr. Med. Res. Opin. 26, 1219–1229 (2010).
Shankar, G., Pendley, C. & Stein, K.E. Nat. Biotechnol. 25, 555–561 (2007).
Macdougall, I.C. et al. N. Engl. J. Med. 361, 1848–1855 (2009).
European Medicines Agency. Scientific Guidance Documents on Biosimilar Medicines (EMA, London; accessed 4 September 2012) <http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002958c&jsenabled=true>
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest relevant to the subject matter or materials discussed in the manuscript. No funding was received for the preparation of this article. This study was performed in the context of the Escher project (T6-202), a project of the Dutch Top Institute Pharma. The division of Pharmacoepidemiology and Clinical Pharmacology, where H.C.E. is employed, has received unrestricted funding for pharmaco-epidemiological research from GlaxoSmithKline, the private-public funded Top Institute Pharma (http://www.tipharma.nl, includes co-funding from universities, government and industry), the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. H.S. participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Part of his research is directly or indirectly sponsored by Roche, Amgen and Sandoz.
Rights and permissions
About this article
Cite this article
Ebbers, H., Crow, S., Vulto, A. et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 30, 1186–1190 (2012). https://doi.org/10.1038/nbt.2438
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2438
This article is cited by
-
Biosimilars in IBD: from theory to practice
Nature Reviews Gastroenterology & Hepatology (2017)
-
Interchangeability of Biosimilars: A European Perspective
BioDrugs (2017)
-
Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
Immunologic Research (2017)
-
Assessing the Immunogenicity of Biopharmaceuticals
BioDrugs (2016)
-
Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
BioDrugs (2016)